( June 4, 2026, 1:51 PM EDT) -- WASHINGTON, D.C. — A unanimous U.S. Supreme Court on June 4 held that a biopharmaceutical company failed to plausibly allege that a bioequivalent maker actively induced patent infringement after considering arguments on the standard of induced infringement in medical patent cases, including ones with “skinny label” generic versions. The high court determined that the patent owner relied on vague language and speculation to attempt to show that the bioequivalent maker induced infringement....